U-46619

U-46619 is a stable synthetic analog of Thromboxane A2 (TXA2), which was first described in the literature in 1975 by scientists at the Upjohn Company. It is commonly used in laboratory research to induce platelet aggregation and blood vessel constriction.

Chemistry

U-46619 is a member of the prostanoid class of compounds, and its chemical structure is similar to that of the naturally occurring eicosanoid, thromboxane A2. The compound is a stable analog, meaning it does not readily degrade in the body, making it useful for laboratory studies.

Pharmacology

U-46619 mimics the action of thromboxane A2, a potent vasoconstrictor and platelet aggregator. It acts by binding to the thromboxane receptor, TP, which is found on the surface of platelets and vascular smooth muscle cells. This binding triggers a series of events leading to platelet aggregation and vasoconstriction.

Uses in Research

U-46619 is widely used in research to study the role of thromboxane A2 in various physiological and pathological processes. It is often used to induce platelet aggregation in vitro, and to cause vasoconstriction in isolated blood vessel preparations. It has also been used to study the effects of various drugs on platelet function and blood vessel tone.

Safety

As a potent vasoconstrictor, U-46619 can cause significant increases in blood pressure if administered systemically. Therefore, it should be used with caution in laboratory animals, and appropriate measures should be taken to monitor and control blood pressure.

See Also

• Thromboxane A2
• Thromboxane receptor
• Platelet aggregation
• Vasoconstriction

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia